Cancer Biology

Discussions of New Developments and Updates

Skip to content
  • Home
  • About
  • Topics
    • Statistics & Epidemiology
      • Incidence
      • Mortality
      • Prevention
      • Diet & Nutrition
    • Biology
      • Cell Cycle
      • Tumor Microenvironment
      • Angiogenesis
      • Invasion & Metastasis
      • Immortalization
      • Stem Cells
      • Heterotypic Cellular Interactions
    • Signal Transduction
      • Receptor Tyrosine Kinase Inhibitors
      • Hormone Receptors
      • Growth Receptors
    • Genetics
      • Oncogenes
      • Tumor Suppressor Genes
      • Mutations
      • Epigenetic Regulation
      • DNA Repair
    • Immunology & Immunotherapy
      • Antibodies & Conjugates
      • Checkpoint Inhibitors
      • Vaccines
      • CAR-T
    • Therapy
      • Traditional Chemotherapy
      • Hormonal
      • Surgery & Radiation
      • Rational Drug Design
      • Off-Target Effects
      • Pharmacokinetics & Pharmacodynamics
      • Resistance
  • SHU Department of Biology
Cancer Biology

Tag Archives: cancer antigens

ImaginAB’s Minibodies for CD8+ T Cell Targeting – Select Optimal Immunotherapy Approaches

ImaginAB and Eli Lilly announced a pre-clinical collaboration to use ImaginAb’s immune imaging agent IAB22M2C to study new T-cell therapies cancer. Continue reading →

This entry was posted in active immunotherapy, Checkpoint Inhibitors, Immunology & Immunotherapy, Uncategorized, Vaccines and tagged cancer antigens, CD8+, checkpoint inhibitors, CTL, cytotoxic T-cell, Eli Lilly, ImaginAB, Minibodies on October 21, 2015 by Joseph Gulfo.


This blog is designed to provide updates in developments in cancer biology and engage in discussions about new findings in the field.

Sponsored by the Department of Biology, Seton Hall University.

@josephgulfo

[fts_twitter twitter_name=@josephgulfo tweets_count=6 cover_photo=no stats_bar=no show_retweets=no show_replies=no]
Proudly powered by WordPress

Pin It on Pinterest